Fresh analysis indicates that people who stop using popular slimming jabs like semaglutide or tirzepatide may regain lost weight far faster than those who end conventional diet and exercise programs.
Research printed in a major medical journal points out that while overweight individuals often shed substantial amounts of their total mass while on the medication, the mass returns at an average rate of 0.8 kg per month once they quit.
"Individuals purchasing these drugs should be informed of the risk of fast rebound weight gain when the treatment concludes," warns lead investigator Dr. Susan Jebb.
This pace of regain implies a reversion to starting mass within about a year and a half.
Weighing Treatments
The research, which examined dozens of trials involving thousands of patients, compared the results of these new drugs with other pills.
Scientists emphasize that people who lose weight through lifestyle changes alone generally have a less rapid creep back—around 0.1 kg a month—after stopping.
The Reason for the Quick Regain
Nutrition scientists suggest the mode of action of the drugs accounts for the heightened rebound.
These medications mimic a natural hormone called GLP-1, which controls feelings of fullness.
"Sustained high doses of GLP-1 levels far above than normal may cause the system to generate a reduced amount of its own natural GLP-1, and may also lessen sensitivity to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this GLP-1 'fix' means hunger is no longer kept in check, making overeating a significant risk."
A Lifelong Disease?
Medical guidelines recommend the injections for people with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
A number of clinicians say that, considering the likelihood of weight regain, the treatment might need to be life-long.
This opinion is echoed by drug manufacturers, who state that the findings "emphasize the persistent nature of excess weight," comparing it to managing diseases like hypertension.
User Experiences
Users who have discontinued the medication report a sudden return of hunger.
"I experienced a trigger flipping and you're instantly extremely hungry," said a patient.
This difficulty is compounded if patients have not developed lasting dietary or behavioural modifications during therapy.
Widespread Use
Figures indicate that a significant number of people in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.
- Adoption is higher among females than males.
- The middle-aged age group shows the highest level of interest.
- Many obtain the medications through private prescriptions rather than the NHS.
Finally, researchers emphasize that while these medications are powerful agents for shedding pounds, they are not a standalone fix and lasting health benefits likely depends on ongoing behavioural management.
